Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10306102 | Psychoneuroendocrinology | 2013 | 5 Pages |
Abstract
A decrease in NGF levels during duloxetine treatment in association to clinical response could be indicative of a relative restoring of NEI stress-adaptation system, since stressors, inducing neuronal instability due to neurotrophins activity changes, permits circuitry remodeling as background in the selection of alternative adaptive behaviors. However, the lower baseline NGF levels found in MDD patients that further decrease during the treatment could represent a lower neurotrophin set point, possibly reflecting a functional impairment in stress-adaptive neuroplasticity in depressive disorders.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Matteo Martino, Giulio Rocchi, Andrea Escelsior, Paola Contini, Salvatore Colicchio, Domenico de Berardis, Mario Amore, Pantaleo Fornaro, Michele Fornaro,